81.4% of the company’s share capital was represented at the general meeting and the resolutions were all approved unanimously
Download the press release in PDF
Geneva, Switzerland, March 20, 2024 – 6:30 p.m. CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), lateral sclerosis amyotrophic (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or COVID-Long), today announces the approval by the shareholders of all the resolutions proposed at the Extraordinary General Meeting (AGEX) of 18 March 2024.